MDXG
HealthcareMiMedx Group, Inc. · Biotechnology · $540M
What is MiMedx Group, Inc.?
MiMedx Group is a small-cap healthcare company specializing in placental tissue allografts — biological products derived from human placental tissue and processed for use in wound care, surgical recovery, and sports medicine applications.
MiMedx develops and distributes placental tissue allografts processed through its patented PURION method, which preserves the tissue's natural biological properties using aseptic techniques and terminal sterilization. The company sells products primarily into wound care, burn treatment, surgical recovery, and non-operative sports medicine markets. It also supplies allografts for dental applications on an original equipment manufacturer basis, broadening its reach across healthcare settings.
Founded in 2008 and headquartered in Marietta, Georgia, MiMedx has built its business around a proprietary tissue-processing platform.
- EpiFix — membrane allograft for chronic wounds including diabetic foot ulcers
- AmnioFix — dehydrated amnion/chorion membrane for surgical recovery
- EpiCord and AmnioCord — umbilical cord allografts for wound and surgical use
- AMNIOBURN — protective allograft for partial- and full-thickness burn treatment
- mdHACM — micronized powder form of AmnioFix for advanced applications
Is MDXG a Good Stock to Buy?
UQS Score rates MDXG as Good overall, reflecting a balanced but nuanced profile across its five quality pillars.
The Risk pillar stands out as a clear strength, suggesting the company carries a relatively manageable financial risk profile for its size and sector. Valuation is rated Attractive, meaning the stock does not appear richly priced relative to its fundamentals — a meaningful consideration for investors evaluating entry points in small-cap healthcare.
The Moat and Growth pillars both register as Weak, indicating limited evidence of durable competitive advantages and below-average near-term growth momentum relative to sector peers.
See the exact pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MDXG pay dividends?
No — MiMedx Group, Inc. does not currently pay a dividend.
MiMedx does not currently pay a dividend. For a small-cap biotech-adjacent company focused on commercializing proprietary tissue allografts, retaining capital for product development, regulatory work, and market expansion is a common strategic priority. Income-focused investors should factor this into their assessment.
When does MDXG report earnings?
MiMedx reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Quarterly results for MiMedx tend to reflect trends in wound care procedure volumes, hospital and outpatient clinic demand, and the company's ability to expand its commercial footprint. Revenue mix across wound care, surgical, and sports medicine channels can shift meaningfully from quarter to quarter.
For the most recent quarter's results and guidance, visit MiMedx's investor relations page directly.
MDXG Price History
-70.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in MiMedx Group, Inc.?
Based on MiMedx Group, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
MDXG Long-term Outlook
The UQS Growth pillar for MDXG is rated Weak, pointing to limited near-term expansion signals relative to healthcare sector peers. However, the Attractive Valuation rating suggests the market may not be pricing in a recovery scenario aggressively. The Strong Risk rating provides some reassurance that the company's financial structure is not a primary concern. The combination of weak growth and attractive valuation is a profile that often attracts patient, value-oriented investors rather than growth-focused ones.
Growth drivers
- Expanding clinical adoption of placental tissue allografts in wound care settings
- Potential market share gains in surgical recovery and sports medicine channels
- OEM dental allograft partnerships providing incremental revenue diversification
Key risks
- Weak Moat rating signals limited pricing power and competitive differentiation risk
- Regulatory and reimbursement changes could affect allograft product coverage
- Small-cap size limits scale advantages versus larger wound care competitors
MDXG vs Peers
MiMedx operates in a competitive healthcare niche alongside companies pursuing different biological and therapeutic approaches.
Contineum focuses on small-molecule drug development for inflammatory and neurological conditions, contrasting with MiMedx's tissue allograft model.
DBV Technologies pursues epicutaneous immunotherapy platforms, representing a distinct biologics approach compared to MiMedx's placental tissue products.
Lexeo is a gene therapy company targeting cardiac and neurological diseases, operating in a different therapeutic modality than MiMedx's regenerative tissue focus.
Frequently Asked Questions
What does MiMedx do?
MiMedx develops and distributes placental tissue allografts processed through its proprietary PURION method. Its products are used primarily in chronic wound care, burn treatment, surgical recovery, and non-operative sports medicine. The company also supplies allografts for dental applications through OEM arrangements.
Does MDXG pay dividends?
MiMedx does not currently pay a dividend. The company retains capital to support its commercial operations and product development efforts, which is typical for small-cap healthcare companies at this stage of growth.
When does MDXG report earnings?
MiMedx follows a standard quarterly earnings cadence for US-listed companies. Specific dates are not covered by our data source — check MiMedx's investor relations page for the most current schedule and recent results.
Is MDXG a good stock to buy?
UQS Score rates MDXG as Good overall. The Risk pillar is Strong and Valuation is Attractive, which may appeal to value-oriented investors. However, both the Moat and Growth pillars are rated Weak, signaling limited competitive differentiation and below-average growth signals. The full pillar breakdown is available to Pro members.
Is MDXG overvalued?
The UQS Valuation pillar for MDXG is rated Attractive, suggesting the stock does not appear expensive relative to its fundamentals. This does not constitute a price prediction, but it does indicate the market is not pricing in aggressive growth expectations at current levels.
How does MDXG compare to its competitors?
MiMedx's closest listed peers — Contineum Therapeutics, DBV Technologies, and Lexeo Therapeutics — operate in different therapeutic modalities, from immunotherapy to gene therapy. MiMedx is differentiated by its focus on placental tissue allografts and its established wound care commercial infrastructure.
What is MDXG's market cap bracket?
MDXG is classified as a small-cap stock. This means it carries characteristics common to smaller publicly traded companies, including potentially higher volatility and more limited analyst coverage compared to large- or mega-cap healthcare names.
Who founded MiMedx?
MiMedx was founded in 2008. Founding details are widely available through public corporate filings and the company's official investor relations materials for those seeking the full historical background.
Is MDXG a long-term quality investment?
From a long-term quality perspective, the UQS Score rates MDXG as Good, with a Strong Risk profile and Attractive Valuation. The Weak Moat rating is a consideration for long-term holders, as durable competitive advantages are a key driver of sustained value creation over time. Pro members can view the complete quality analysis.
What is the main competitive advantage of MiMedx?
MiMedx's primary differentiator is its patented PURION processing technology, which preserves the biological properties of placental tissue allografts. However, the UQS Moat pillar is rated Weak, suggesting this advantage may not yet translate into a wide or durable competitive moat relative to sector peers.
What sector does MDXG belong to?
MiMedx operates in the Healthcare sector, specifically within regenerative medicine and advanced wound care. Its products sit at the intersection of biologics and medical devices, serving hospitals, outpatient wound care centers, and surgical facilities.
Unlock Full MDXG Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across all five dimensions
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare MDXG against sector peers on quality and valuation
- ✓Track score changes as new earnings data is released
- ✓Screen for similar small-cap healthcare stocks by pillar profile
Pro Analysis
MDXG — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 52.4 | 61.3 | 28.0 | 26.7 | 100.0 | 64.9 | -5.2 |
| May 3, 2026 | 57.6 | 76.7 | 28.0 | 26.7 | 100.0 | 73.9 | -0.2 |
| May 2, 2026 | 57.8 | 76.7 | 28.0 | 26.7 | 100.0 | 74.9 | -1.6 |
| May 1, 2026 | 59.4 | 76.7 | 28.0 | 27.3 | 100.0 | 85.2 | -0.1 |
| Apr 24, 2026 | 59.5 | 76.7 | 28.0 | 27.6 | 100.0 | 85.3 | -0.3 |
| Apr 19, 2026 | 59.8 | 76.7 | 28.0 | 28.2 | 100.0 | 86.2 | -0.2 |
| Apr 18, 2026 | 60.0 | 76.7 | 28.0 | 29.8 | 100.0 | 85.4 | +0.8 |
| Apr 14, 2026 | 59.2 | 76.7 | 28.0 | 29.8 | 100.0 | 80.1 | -0.1 |
| Apr 12, 2026 | 59.3 | 76.7 | 28.0 | 29.8 | 100.0 | 80.7 | +0.1 |
| Apr 5, 2026 | 59.2 | 76.7 | 28.0 | 29.8 | 100.0 | 80.2 | +0.1 |
MDXG — Pillar Breakdown
Quality
— 61.3/100 (25%)MiMedx Group, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 26.7/100 (20%)MiMedx Group, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 100.0/100 (15%)MiMedx Group, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 65.4/100 (15%)MiMedx Group, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 28/100 (25%)MiMedx Group, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MDXG.
Score Composition
Financial Data
More Stock Analysis
How is the MDXG UQS Score Calculated?
The UQS (Unified Quality Score) for MiMedx Group, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses MiMedx Group, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether MiMedx Group, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.